Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 HKD | +1.43% | +4.41% | -2.74% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Business Summary
Number of employees: 219
Sales per Business
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 63 | 100.0 % | 63 | 100.0 % | -0.57% |
Sales per region
HKD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
100.0
%
| 63 | 100.0 % | 63 | 100.0 % | -0.53% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Yan Yuemei
CTO | Chief Tech/Sci/R&D Officer | - | - |
Handan He
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-06 |
Zhengqing Li
CTO | Chief Tech/Sci/R&D Officer | - | 19-02-27 |
Chief Operating Officer | 50 | 19-03-12 | |
Joshua Zhongbao
PRN | Corporate Officer/Principal | - | 18-08-29 |
Ming Fai Chung
SEC | Corporate Secretary | 45 | 22-08-21 |
John Gargiulo
PRN | Corporate Officer/Principal | - | 22-06-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jinzi Wu
CEO | Chief Executive Officer | 61 | - |
Jiong Gu
BRD | Director/Board Member | 51 | 18-03-31 |
Chief Operating Officer | 50 | 19-03-12 | |
Yizhen Wei
BRD | Director/Board Member | 49 | 18-04-26 |
Lin Hua
BRD | Director/Board Member | 50 | 18-04-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,012,758,000 | 286,381,323 ( 28.28 %) | 0 | 28.28 % |
Company contact information
Ascletis Pharma, Inc.
HIPARK, 198 Qidi Road Xiaoshan District
311200, Hangzhou
+86 571 8538 9730
http://www.ascletis.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.74% | 181M | |
-3.79% | 87.06B | |
+1.45% | 40.25B | |
-15.94% | 31.09B | |
+52.66% | 24.74B | |
-14.50% | 15.91B | |
-9.12% | 11.96B | |
-14.38% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- 1672 Stock
- Company Ascletis Pharma Inc.